Multifactorial Intervention to Reduce Cardiovascular Events in Type 2 Diabetes

被引:16
|
作者
Rajpathak, Swapnil N. [2 ]
Aggarwal, Vikas [2 ]
Hu, Frank B. [1 ]
机构
[1] Harvard Univ, Sch Publ Hlth, Dept Nutr & Epidemiol, Boston, MA 02115 USA
[2] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, New York, NY USA
关键词
Diabetes; Cardiovascular disease; Multifactorial intervention; Lifestyle intervention; Nutrition; Lipids; Obesity; Hypertension; Hypoglycemia; CORONARY-HEART-DISEASE; WHOLE-GRAIN INTAKE; GLUCOSE CONTROL; DIETARY FIBER; GLYCEMIC LOAD; COST-EFFECTIVENESS; PHYSICAL-ACTIVITY; TOTAL MORTALITY; RISK; MELLITUS;
D O I
10.1007/s11892-009-0084-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Type 2 diabetes is associated with a significantly increased risk of cardiovascular disease (CVD) morbidity and mortality. Although several clinical trials have evaluated the effects of interventions to reduce CVD risk in people with diabetes, such studies are primarily conducted to target individual risk factors such as hypertension, hyperglycemia, and dyslipidemia rather than using a multifactorial interventional approach. Existing clinical trial data suggest that intensive multifactorial interventions that target several important risk factors simultaneously result in a significantly greater risk reduction in CVD risk compared with single risk factor interventions. However, few studies have evaluated the efficacy and effectiveness of such interventions on CVD hard end points. A multidisciplinary team management of diabetes should focus on weight control, diet, physical activity, diabetes education, and adherence to pharmacotherapy. An individually tailored aggressive management program to reduce multiple CVD risk factors simultaneously has great potential to prevent CVD morbidity and mortality among patients with type 2 diabetes.
引用
收藏
页码:16 / 23
页数:8
相关论文
共 50 条
  • [31] Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria:: the Steno type 2 randomised study
    Gæde, P
    Vedel, P
    Parving, HH
    Pedersen, O
    LANCET, 1999, 353 (9153): : 617 - 622
  • [32] Intensified multifactorial intervention in patients with type 2 diabetes mellitus: Phenotypes of retinopathy progression
    Duarte, LG
    Figueira, JP
    Nunes, SG
    Bernardes, RC
    Geraldes, ES
    Cunha-Vaz, JG
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2005, 46
  • [33] Long-term effects of multifactorial intervention in patients with type 2 diabetes mellitus
    Jecht, M.
    DIABETOLOGE, 2016, 12 (08): : 580 - 581
  • [34] Assessment of the costs and benefits from a lifestyle intervention to reduce cardiovascular disease among persons with type 2 diabetes
    Sorensen, S
    Hicks, K
    Hoerger, T
    Narayan, KMV
    Williamson, DF
    Thompson, T
    Zhang, P
    Engelgau, M
    DIABETES, 2005, 54 : A608 - A608
  • [35] Target intervention against multiple-risk markers to reduce cardiovascular disease in patients with type 2 diabetes
    Gæde, P
    Pedersen, O
    ANNALS OF MEDICINE, 2004, 36 (05) : 355 - 366
  • [36] Outcomes of a multifactorial cardiovascular prevention programme in patients with type 2 diabetes: An observational study
    Finn, Y.
    Gorecka, M.
    Flaherty, G.
    Dunne, F.
    O'Brien, T.
    Crowley, J.
    Woods, D.
    Connolly, S.
    Jones, J.
    Gibson, I.
    DIABETIC MEDICINE, 2020, 37 : 74 - 75
  • [37] Sociocultural Tailoring of a Healthy Lifestyle Intervention to Reduce Cardiovascular Disease and Type 2 Diabetes Risk Among Latinos
    Mudd-Martin, Gia
    Martinez, Maria C.
    Rayens, Mary Kay
    Gokun, Yevgeniya
    Meininger, Janet C.
    PREVENTING CHRONIC DISEASE, 2013, 10 : E200
  • [38] Flavanol-rich cocoa - A promising new dietary intervention to reduce cardiovascular risk in type 2 diabetes?
    Campia, Umberto
    Panza, Julio A.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 51 (22) : 2150 - 2152
  • [39] Influence of Microvascular Disease on Cardiovascular Events in Type 2 Diabetes
    Verma, Subodh
    Wanner, Christoph
    Zwiener, Isabella
    Ofstad, Anne Pernille
    George, Jyothis T.
    Fitchett, David
    Zinman, Bernard
    Aizenberg, D.
    Ulla, M.
    Waitman, J.
    De Loredo, L.
    Farias, J.
    Fideleff, H.
    Lagrutta, M.
    Maldonado, N.
    Colombo, H.
    Ferre Pacora, F.
    Wasserman, A.
    Maffei, L.
    Lehman, R.
    Selvanayagam, J.
    d'Emden, M.
    Fasching, P.
    Paulweber, B.
    Toplak, H.
    Luger, A.
    Drexel, H.
    Prager, R.
    Schnack, C.
    Schernthaner, G.
    Fliesser-Goerzer, E.
    Kaser, S.
    Scheen, A.
    Van Gaal, L.
    Hollanders, G.
    Kockaerts, Y.
    Capiau, L.
    Chachati, A.
    Persu, A.
    Hermans, M.
    Vantroyen, D.
    Vercammen, C.
    Van de Borne, P.
    Mathieu, C.
    Benhalima, K.
    Lienart, F.
    Mortelmans, J.
    Strivay, M.
    Vereecken, G.
    Keymeulen, B.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (21) : 2780 - 2782
  • [40] Atorvastatin reduces cardiovascular events in patients with type 2 diabetes
    不详
    DIABETES OBESITY & METABOLISM, 2003, 5 (06): : 472 - 472